Abstract: A functional film 1 according to an embodiment includes: a substrate (10) containing an acetyl cellulose resin; a primer layer (20) containing a filler (40) and disposed on the substrate (10); and a functional layer (30) containing the filler (40) and disposed on the primer layer (20). The substrate (10) has a permeation layer (12) formed by permeation of the resin contained in the primer layer (20) into part of the substrate (10). The permeation layer (12) has a thickness of 0.1 ?m or more and 3.5 ?m or less. The primer layer (20) has a thickness of 0.1 ?m or more and 1.0 ?m or less. The filler (40) is silica particles having an average particle size of 20 nm or more and 80 nm or less. The filler (40) in the primer layer (20) has a density of ? or more and ¾ or less of the density of the filler (40) in the functional layer (30). The primer layer (20) and the functional layer (30) each contain a resin. The resin component of the primer layer (20) is the same as the resin component of the functional layer 30.

Abstract: A functional film includes: an acetyl cellulose resin substrate; a primer layer containing a filler and disposed on the substrate; and a functional layer containing the filler and disposed on the primer layer. The substrate has a permeation layer formed by permeation of the resin contained in the primer layer into part of the substrate. The permeation layer has a thickness of 0.1 ?m-3.5 ?m. The primer layer has a thickness of 0.1 ?m-1.0 ?m. The filler is silica particles having an average particle size of 20 nm-80 nm. The filler in the primer layer has a density of ?-¾ of the density of the filler in the functional layer. The primer layer and the functional layer each contain a resin. The resin component of the primer layer is the same as the resin component of the functional layer.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: A samarium-iron-nitrogen based magnet powder includes a lanthanoid (Ln), iron (Fe), bismuth (Bi), tungsten (W), and nitrogen (N), wherein the lanthanoid includes samarium (Sm), an atomic ratio of bismuth to a 5 sum of the lanthanoid, iron, bismuth, and tungsten (Bi/(Ln+Fe+Bi+W)) is 1.00 at % or less, an atomic ratio of tungsten to the sum of the lanthanoid, iron, bismuth, and tungsten (W/(Ln+Fe+Bi+W)) is 0.05 at % or more and 0.60 at % or less, and an atomic ratio of tungsten to bismuth (W/Bi) is 1.0 or more and 30.0 or less.

Abstract: A coil component includes an element body formed by laminating a plurality of insulator layers, and a pillar part disposed in the element body and extending in a lamination direction of the plurality of insulator layers. The pillar part has a plurality of pillar members laminated in the lamination direction. Between the two pillar members in the lamination direction, a defining part that defines a contact surface between the two pillar members is provided. The defining part is formed of a material different from a material of the pillar part, and is disposed at edges of the two pillar members when viewed from the lamination direction.

Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, 10 addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st X to the 12th X counting from the amino terminus.

Abstract: A coil component includes an element body formed by stacking a plurality of insulating layers and including a principal surface and a principal surface, a first terminal electrode and a second terminal electrode disposed on the principal surface of the element body, and a coil disposed in the element body and electrically connected to the first terminal electrode and the second terminal electrode. The coil includes a first wiring portion disposed on the principal surface side, a second wiring portion disposed on the principal surface side, and a pillar portion extending in the second direction and connecting the first wiring portion and the second wiring portion. In the pillar portion, a filler is disposed on a contact surface in which two conductors come into contact with each other.

Abstract: An electronic component includes: an element body having a main surface as a mounting surface; a coil portion having a coil pattern formed by a plurality of coil conductors in the element body; and a pair of external electrodes formed on the main surface of the element body and electrically connected to the coil portion, the external electrode includes a first electrode layer exposed from the main surface of the element body and a second electrode layer embedded in the element body, the first electrode layer includes a first region overlapping the second electrode layer and a second region not overlapping the second electrode layer when viewed from a first direction perpendicular to the main surface, the second region overlaps the coil conductor when viewed from the first direction, and the second electrode layer has an extended portion protruding from an outer edge of the first electrode layer.

Abstract: An electronic component includes: an element body having a main surface as a mounting surface; and a pair of external electrodes including an electrode layer embedded inside an opening of the element body and a plating layer formed on the electrode layer, in a first direction perpendicular to the main surface, a main surface of the electrode layer is disposed deeper inside the element body than a virtual plane obtained by virtually extending the main surface in the opening, and the plating layer is formed on the main surface of the electrode layer and covers the electrode layer so as to extend from the virtual plane to a main surface of the element body.

Abstract: It is intended to provide a novel peptide. The present invention provides a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits protease activity.

Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Abstract: A functional film 1 according to an embodiment includes: a substrate (10) containing an acetyl cellulose resin; a primer layer (20) containing a filler (40) and disposed on the substrate (10); and a functional layer (30) containing the filler (40) and disposed on the primer layer (20). The substrate (10) has a permeation layer (12) formed by permeation of the resin contained in the primer layer (20) into part of the substrate (10). The permeation layer (12) has a thickness of 0.1 ?m or more and 3.5 ?m or less. The primer layer (20) has a thickness of 0.1 ?m or more and 1.0 ?m or less. The filler (40) is silica particles having an average particle size of 20 nm or more and 80 nm or less. The filler (40) in the primer layer (20) has a density of ? or more and ¾ or less of the density of the filler (40) in the functional layer (30). The primer layer (20) and the functional layer (30) each contain a resin. The resin component of the primer layer (20) is the same as the resin component of the functional layer 30.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.

Abstract: One embodiment of the present invention includes, in a samarium-iron-nitrogen based magnet powder, a main phase containing samarium and iron, and a sub-phase containing samarium, iron, and at least one or more elements selected from the group consisting of zirconium, molybdenum, vanadium, tungsten, and titanium, wherein an atomic ratio of a rare earth element to an iron group element is greater than an atomic ratio of the rare earth element to the iron group element of the main phase, wherein at least a part of a surface of the main phase is coated with the sub-phase.

Abstract: A novel antibody that can be used as an anti-tumor agent and an anti-tumor agent that comprises, as an active ingredient, a molecule containing such an antibody.

Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.

Abstract: A samarium-iron-nitrogen based magnet, wherein a samarium oxide phase is formed on at least a part of a surface of a crystal grain, and wherein an atomic ratio of calcium to a total amount of iron group elements, rare earth elements, and calcium is 0.4% or less.